OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 16; no. 3; p. S103
Main Authors Krebs, M.G., Helland, Å., Carcereny Costa, E., Arriola Aperribay, E., Dómine Gómez, M., Trigo Pérez, J., Thompson, J., Strauss, J., Ortega Granados, A.L., Felip, E., Schmidt, E., Chisamore, M., Madeleine, N., Rayford, A., Lorens, K., Siddiqui, A., Gabra, H., Nautiyal, J., Micklem, D., Lorens, J., Spicer, J.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.03.2021
Online AccessGet full text

Cover

More Information
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2021.01.275